F.D.A. Declines to Approve MDMA Therapy, Seeking More Study
Posted inClinical Trials Drug Enforcement Administration Drugs (Pharmaceuticals) Ecstasy (Drug) Food and Drug Administration LSD (Lysergic Acid Diethylamide) Lykos Therapeutics Mental Health and Disorders Post-Traumatic Stress Disorder Psilocybin Mushrooms Psychedelic and Hallucinogenic Drugs Psychology and Psychologists Regulation and Deregulation of Industry Research Therapy and Rehabilitation Veterans

F.D.A. Declines to Approve MDMA Therapy, Seeking More Study

The agency said there was insufficient data to allow the use of a treatment for PTSD that involves the drug known as Ecstasy, according to the company seeking approval.
Veterans and Lawmakers Lobby for Approval of MDMA Therapy
Posted inBergman, Jack (1947- ) Clinical Trials Depression (Mental) Drugs (Pharmaceuticals) Ecstasy (Drug) Food and Drug Administration House of Representatives Institute for Clinical and Economic Review LSD (Lysergic Acid Diethylamide) Lykos Therapeutics Mental Health and Disorders Post-Traumatic Stress Disorder Psilocybin Mushrooms Psychedelic and Hallucinogenic Drugs Psychiatry and Psychiatrists Regulation and Deregulation of Industry Research Therapy and Rehabilitation Veterans

Veterans and Lawmakers Lobby for Approval of MDMA Therapy

The F.D.A. is poised to rule on the therapeutic use of the club drug Ecstasy, a potential watershed moment in the nascent field of psychedelic medicine.
New Drug Approved for Early Alzheimer’s
Posted inAlzheimer's Disease Biogen Inc Brain Clinical Trials Dementia Drugs (Pharmaceuticals) Eisai Co Ltd Eli Lilly and Company Food and Drug Administration Leqembi (Drug) Memory Placebos Prices (Fares, Fees and Rates) your-feed-healthcare your-feed-science

New Drug Approved for Early Alzheimer’s

The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.